ClinicalTrials.gg
CompletedNCT00426179Updated Nov 19, 2007

Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen

A Phase 1/2 interventional study of Imatinib in Seasonal Allergic Rhinitis, sponsored by Novartis. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2007-11-19.

Sponsored by Novartis · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Rhinitis, Allergic, Seasonal by Novartis — none open to participants now, none under way, none of them phase 3. Rhinitis, Allergic, Seasonal · Novartis.

Planned enrollment
10th of 10
30 · median 191
Started
2006
the only one that year
Phase 1/2
Only one
of the 11
Registered
1st of 11
by date

Among the 11 studies in Rhinitis, Allergic, Seasonal by Novartis, this one is the 10th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2006, is the only one in phase 1/2, and was the 1st registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

None of the 11 studies in Rhinitis, Allergic, Seasonal by Novartis is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 55 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Rhinitis, Allergic, Seasonal by Novartis as a file.
02

Study summary

This study will assess the effects of Imatinib on allergic inflammation following repeated nasal allergen challenge in subjects with seasonal allergic rhinitis sensitive to Timothy grass pollen.

03

Conditions studied

  • Seasonal Allergic Rhinitis

Keywords

  • Imatinib, allergic inflammation, out of allergy season, repeated nasal allergen, seasonal allergic rhinitis, sensitive, Timothy grass pollen, c-kit inhibition
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male non-smoking subjects aged 18-55 years, with a history of seasonal allergic rhinitis consistent with Timothy grass pollen allergy. They must show: a positive skin prick test to Timothy grass pollen (wheal difference Timothy grass pollen - negative control ≥ 3 mm) at or within the 12 months preceding the screening visit and demonstrate symptomatic worsening (TNSS ≥4) within one hour after nasal allergen challenge
  • Be otherwise healthy with no health problems that may jeopardize the subjects participating in the study, absence of history of other significant allergies.
  • Subjects and their partners must agree to use effective measures from screening until the end of study visit.

Exclusion criteria

Exclusion Criteria:

  • Respiratory disease other than a history of mild stable asthma not requiring treatment and associated with normal lung function.
  • Structural nasal abnormalities or nasal polyps on examination, a history of frequent nose bleeding, recent nasal surgery or recent (within 8 weeks prior to baseline visit) or recent (four weeks) or ongoing upper or lower respiratory tract infection.
  • Use of any medication that would affect the response to the allergen challenge (e.g. , decongestants, anti-histamines, medications with anti-inflammatory effects) or any other nasally applied medication within 14 days prior to allergen challenge (30 days for systemic anti-inflammatory therapy including oral corticosteroids), or known to influence Imatinib bioavailability or clearance
  • History or laboratory evidence of acute or chronic renal insufficiency or abnormal liver function.
  • Subjects may voluntarily withdraw from or be withdrawn from the study at the discretion of the investigator or the sponsor at any time. Subjects may be withdrawn from the study prematurely for one of the following reasons:
  • Subject withdrew consent
  • Upper respiratory tract infection
  • Presence of allergic rhinitis symptoms in the screening period or prior to pre-wash on Day 1
  • A past medical history of inherited heart disease, valve defect, cardiomyopathy, rheumatic fever, arrhythmias, cardiac interventions or abnormalities.
  • Adverse events and non-tolerable symptoms resulting from allergen challenge
  • Administration of a concomitant medication (other than those randomized to receive Fluticasone propionate) that would impact on the study results (e.g. corticosteroids), including any subjects requiring asthma therapy (inhaled or systemic).

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
30 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Effect of Imatinib on the reduction of mast cell degranulation (measured by β-tryptase and PGD2) in response to allergen challenge

Secondary outcomes

  1. Additional markers of inflammation following nasal allergen challenge (NAC):

  2. Enumeration of eosinophils in nasal lavage following NAC

  3. Total nasal symptom score (TNSS) following NAC

  4. Soluble mediators collected from adsorption onto nasal filter papers following NAC, with a focus on Th2-associated cytokines

07

Study locations

1 site
  • Novartis Investigative site
    Horsham, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2007
First posted
Jan 24, 2007
Start
Dec 2006
CompletionActual
Aug 2007
Last update
Nov 19, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00426179
Lead sponsor
Novartis
First posted
Jan 24, 2007
Start date
Dec 2006
Completion
Aug 2007
Last update
Nov 19, 2007

Study contacts

Novartis
principal investigator · Investigative site
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion